Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N
| Autor: | Makker, Vicky, Filiaci, Virginia L., Chen, Lee-may, Darus, Christopher J., Kendrick, James E., Sutton, Gregory, Moxley, Katherine, Aghajanian, Carol |
|---|---|
| Zdroj: | In Gynecologic Oncology July 2015 138(1):24-29 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect